LOS ANGELES - For patients with early kidney cancer, removing part of the kidney instead of the whole kidney is often a preferred treatment because the procedure can effectively remove tumors while preserving kidney function. But when it comes to the best surgical approach -- robotic, laparoscopic or open -- for this type of surgery, known as partial nephrectomy, the choice has been less clear. A comprehensive study by the Keck School of Medicine of USC, which has found that robotic partial nephrectomy offers significantly better patient outcomes, may help inform those decisions.
"Robotic partial nephrectomy has become increasingly more common, yet there's a lack of consensus among urologists about its performance vis-a-vis open or laparoscopic techniques," says the study's corresponding author Inderbir Gill, MD, chair and distinguished professor of urology at the Keck School. "Our goal with this study was to critically evaluate the impact of these three techniques on patient outcomes such as complications, cancer recurrence and mortality."
The systematic review and meta-analysis, published in the August 2018 issue of The Journal of Urology, combined data from 98 studies on robotic, open and laparoscopic partial nephrectomy. More than 20,000 patients were included in the analysis.
When comparing robotic to open partial nephrectomy, the study found that robotic partial nephrectomy offered several superior patient outcomes, including decreased complications during and after surgery, cancer recurrence, overall mortality, hospital length of stay and readmission. There was no difference in cancer-specific mortality between the two techniques.
Results also showed that robotic partial nephrectomy was equivalent to, and sometimes better than, laparoscopic partial nephrectomy. While there was no difference in cancer recurrence, cancer-specific mortality, length of hospital stay or readmission, a robotic technique was associated with lower overall mortality and fewer complications during and after surgery.
Gill, who is the executive director of the USC Institute of Urology at Keck Medicine of USC, believes the data suggest that the technique of robotic partial nephrectomy has now become established in the field.
"Our study shows that robotic partial nephrectomy is not only safe and effective but also a preferred approach for treating small kidney tumors," he says.
Kidney cancer is among the 10 most common cancers, affecting 1 in 48 men and 1 in 83 women. According to the American Cancer Society, the rate of kidney cancer has been rising since the 1990s, but the mortality rate has decreased slightly since then. The society predicts that about 63,000 Americans will be diagnosed with kidney cancer this year.
About the Keck School of Medicine of USC
Founded in 1885, the Keck School of Medicine of USC is among the nation's leaders in innovative patient care, scientific discovery, education and community service. It is part of Keck Medicine of USC, the University of Southern California's medical enterprise, one of only two university-owned academic medical centers in the Los Angeles area. This includes Keck Medical Center of USC, composed of Keck Hospital of USC and USC Norris Cancer Hospital. The two world-class, USC-owned hospitals are staffed by more than 500 physicians who are faculty at the Keck School. The school has more than 1,750 full-time faculty members and voluntary faculty of more than 2,400 physicians. These faculty direct the education of approximately 800 medical students and 1,000 students pursuing graduate and postgraduate degrees. The school trains more than 900 resident physicians in more than 50 specialty or subspecialty programs and is the largest educator of physicians practicing in Southern California. Together, the school's faculty and residents serve more than 1.5 million patients each year at Keck Hospital of USC and USC Norris Cancer Hospital, as well as USC-affiliated hospitals, Children's Hospital Los Angeles and Los Angeles County + USC Medical Center. Keck School faculty also conduct research and teach at several research centers and institutes, including the Eli and Edythe Broad Center for Stem Cell Research and Regenerative Medicine at USC, USC Cardiovascular Thoracic Institute, USC Institute of Urology, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, USC Norris Comprehensive Cancer Center, USC Roski Eye Institute and Zilkha Neurogenetic Institute.
In 2018, U.S. News & World Report ranked the Keck School among the top 35 medical schools in the country.
For more information, go to keck.usc.edu.